BidaskClub cut shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, BidAskClub reports.. Other analysts have also issued reports about the stock. Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The stock traded as low as $5.73 and last traded at $5.77, 1,728,246 shares traded hands during mid-day trading. The stock had previously closed at $6.12. Trillium Therapeutics Downgraded by BidaskClub on 7/7/2020.
The analysts previously had rating of Buy. A decline of 58% from the average session volume of 4,092,538 shares. Several other research firms have also commented on TRIL. Cambridge Office.
Trillium Therapeutics Inc. Common Shares (TRIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. View detailed financial information, real-time news, videos, quotes and analysis on Trillium Therapeutics Inc. (NASDAQ:TRIL). Analyzing Trillium Therapeutics (NASDAQ:TRIL) stock? Online Stock Comparison - Compare Trillium Therapeutics Inc. (TRIL) to four other stocks with NASDAQ.com's stock comparison tool.
Trillium Therapeutics Inc. (NASDAQ:TRIL) trade information.
NASDAQ Last Sale (NLS) Intraday Stock History Report: Time and sales data for Trillium Therapeutics Inc. (TRIL) Based on an average trading volume of 2,130,000 shares, the short-interest ratio […] A decline of 58% from the average session volume of 4,092,538 shares. The stock traded as low as $5.73 and last traded at $5.77, 1,728,246 shares traded hands during mid-day trading. Find the latest analyst research for Trillium Therapeutics Inc. Common Shares (TRIL) ... Stock Alert: Trillium Therapeutics Gains 28% After Gilead Acquires Forty Seven Mar 2, ... Nasdaq… Shares of Trillium Therapeutics traded no change $0.00 on Monday, reaching $7.61.
As of June 30th, there was short interest totalling 6,340,000 shares, an increase of 8.4% from the June 15th total of 5,850,000 shares.
TRIL, Trillium Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines The results of the director elections were as follows: Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR)’s share price traded down 5.7% during mid-day trading on Thursday . ET by Tomi Kilgore Barron's In the face of being in the red today for losing -4.2%, in the last five days TRIL remained trading in the green while hitting it’s week-highest on Wednesday, Jul 01 when the stock touched $8.38-1 … Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was downgraded by equities researchers at BidaskClub from a "buy" rating to a "hold" rating in a research note issued to investors on Tuesday, BidAskClub reports.
1967 shares of the stock traded hands, compared … In the face of being in the red today for losing -4.2%, in the last five days TRIL remained trading in the green while hitting it’s week-highest on Wednesday, Jul 01 when the stock touched $8.38-1 price level, adding 13.01% to its value on the day. The stock had previously closed at $6.12. In a note to investors, the firm issued a new rating of Hold. ValuEngine upgraded shares of Trillium Therapeutics from a sell rating to a hold rating in a research note on Thursday, April 2nd. Trillium Therapeutics stock has undergone multiple analysts rating changes in the recent past. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 At the end of the third quarter, a total of 4 of the hedge funds tracked by Insider Monkey were long this stock… View TRIL's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Real time Trillium Therapeutics (TRIL) stock price quote, stock graph, news & analysis.